Alexion Pharma (ALXN): Could Be The Last Complement Inhibitor Standing - Leerink
- Wall Street dips as Verizon drags; AmEx curbs losses
- Unusual 11 Mid-Day Movers 10/20: (DRWI) (MBRX) (SPU) Higher; (RIGL) (FLXS) (DXPE) Lower
- Tesla (TSLA) Announces Self-Driving Hardware for All Vehicles in Production; Includes Model 3
- Walgreens Boots Alliance (WBA) Tops Q4 EPS by 8c; Guides FY17 EPS
- Verizon Communications (VZ) Tops Q3 EPS by 2c
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) and raised his price target to $211 from $210 on the belief that the company's flagship complement inhibition franchise is likely to remain the dominant, if not only, terminal complement inhibitor on the market.
The analyst's research found that the growing number of manufacturers with competing programs in early stage development face significant technical and market-related challenges to match or surpass Soliris. Given the stage of development, any rival program obtaining approval would enter the market after Alexion’s ALXN1210, and its more convenient dosing schedule will be a significant advantage over most competitors. The analyst views Alexion’s complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases.
The $1 increase is due to an update in the company's financials as they flow through the analyst's average of PE, PEG and DCF.
Shares of Alexion Pharmaceuticals closed at $127.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xilinx (XLNX) PT Bumped to $45 at Nomura, Remains Sidelined
- Wedbush Cuts Price Target on Tractor Supply (TSCO) to $65 Following 3Q
- Wedbush Cuts Price Target on eBay (EBAY) Following 3Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!